PHAXIAM Therapeutics Gestione

Gestione criteri di controllo 2/4

PHAXIAM Therapeutics Il CEO è Thibaut Fayet, nominato in Jun2023, e ha un mandato di 1.42 anni. la retribuzione annua totale è € 391.73K, composta da 34.5% di stipendio e 65.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.055% delle azioni della società, per un valore di € 9.44K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.4 anni e 11.5 anni.

Informazioni chiave

Thibaut Fayet

Amministratore delegato

€391.7k

Compenso totale

Percentuale dello stipendio del CEO	34.5%
Mandato del CEO	1.4yrs
Proprietà del CEO	0.05%
Durata media del management	1.4yrs
Durata media del Consiglio di amministrazione	11.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Thibaut Fayet rispetto agli utili di PHAXIAM Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

Compensazione vs Mercato: La retribuzione totale di Thibaut ($USD 407.96K ) è circa la media per le aziende di dimensioni simili nel mercato French ($USD 324.83K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Thibaut con le performance aziendali.

AMMINISTRATORE DELEGATO

Thibaut Fayet (56 yo)

1.4yrs

Mandato

€391,725

Compensazione

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 9.4k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 651.0
Frédéric Mathat	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Cindy Fevre	Chief Scientific Officer	1.8yrs	Nessun dato	Nessun dato
Naomi Eichenbaum	Director Investor Relations	no data	Nessun dato	Nessun dato
Pascal Birman	Chief Medical Officer	1.4yrs	Nessun dato	Nessun dato
Philip Lorenzi	Consultant & Member of Scientific Board	no data	Nessun dato	Nessun dato
Eric Raymond	Consultant & Member of Scientific Board	no data	Nessun dato	Nessun dato
Bridget Bax	Consultant & Member of Scientific Board	no data	Nessun dato	Nessun dato
Arthur Frankel	Consultant & Member of Scientific Board	no data	Nessun dato	Nessun dato
Kurt Gunter	Consultant & Member of Scientific Board	no data	Nessun dato	Nessun dato

1.4yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di PHXM non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	Nessun dato	Nessun dato
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	Nessun dato	Nessun dato
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	Nessun dato	Nessun dato
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	Nessun dato	Nessun dato
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	Nessun dato	Nessun dato
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.8k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 831.9
Hilde Windels	Independent Director	10.2yrs	€56.75k	Nessun dato
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	Nessun dato
Leila Nicolas	Representative Director	1.4yrs	€26.25k	Nessun dato
Robert Sebbag	Independent Director	1.4yrs	€21.75k	Nessun dato
Valerie Faillat	Independent Director	less than a year	Nessun dato	Nessun dato

11.5yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHXM è composto da personale esperto e esperto (durata media dell'incarico 11.5 anni).

PHAXIAM Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Price target decreased to €5.80

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Analysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long

Price target decreased to €14.50

Consensus forecasts updated

Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

Analysts update estimates

Earnings beat expectations, revenue disappoints

New 90-day low: €6.63

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years

New 90-day high: €8.88

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?

New 90-day high: €8.02

New 90-day high: €6.50

Analysts update estimates

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.24

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.95

New 90-day low - €5.51

New 90-day low - €6.06

New 90-day low - €6.74

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media